Context Therapeutics (CNTX) Competitors $0.84 0.00 (-0.12%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.85 +0.02 (+1.80%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. TVRD, NGNE, LFCR, MREO, ACB, RNAC, CADL, MNPR, NMRA, and LXEOShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Tvardi Therapeutics (TVRD), Neurogene (NGNE), Lifecore Biomedical (LFCR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), Neumora Therapeutics (NMRA), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors Tvardi Therapeutics Neurogene Lifecore Biomedical Mereo BioPharma Group Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Lexeo Therapeutics Tvardi Therapeutics (NASDAQ:TVRD) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Do analysts prefer TVRD or CNTX? Tvardi Therapeutics presently has a consensus target price of $64.25, suggesting a potential upside of 89.64%. Context Therapeutics has a consensus target price of $5.25, suggesting a potential upside of 528.74%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Tvardi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is TVRD or CNTX more profitable? Context Therapeutics has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -678.79%. Context Therapeutics' return on equity of -38.80% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics-678.79% -565.83% -66.71% Context Therapeutics N/A -38.80%-37.53% Do institutionals & insiders have more ownership in TVRD or CNTX? 44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 3.1% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 2.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, TVRD or CNTX? Tvardi Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Which has preferable valuation & earnings, TVRD or CNTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTvardi TherapeuticsN/AN/A-$70.87MN/AN/AContext TherapeuticsN/AN/A-$26.73M-$0.36-2.32 Does the media prefer TVRD or CNTX? In the previous week, Context Therapeutics had 4 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for Context Therapeutics and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.89 beat Context Therapeutics' score of 0.88 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tvardi Therapeutics Very Positive Context Therapeutics Positive SummaryContext Therapeutics beats Tvardi Therapeutics on 10 of the 13 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.99M$2.60B$5.86B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-2.3223.8575.0625.97Price / SalesN/A529.66514.97181.20Price / CashN/A171.1637.5660.44Price / Book0.665.3712.156.29Net Income-$26.73M$32.95M$3.29B$270.96M7 Day Performance1.78%1.28%0.75%3.87%1 Month Performance19.29%6.09%4.82%4.88%1 Year Performance-60.05%-2.15%60.59%26.12% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.5104 of 5 stars$0.84-0.1%$5.25+528.7%-61.2%$74.99MN/A-2.327News CoverageShort Interest ↓TVRDTvardi Therapeutics2.7421 of 5 stars$29.66-4.7%$64.25+116.6%N/A$291.73M$7.14M0.0080Positive NewsNGNENeurogene2.1484 of 5 stars$19.45-2.5%$46.17+137.4%-52.9%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical1.1086 of 5 stars$7.29-3.2%$8.00+9.7%+46.9%$281.68M$128.87M-5.56690MREOMereo BioPharma Group2.4388 of 5 stars$1.79+1.1%$7.40+313.4%-57.9%$281.43M$10M-25.5740Positive NewsACBAurora Cannabis0.497 of 5 stars$4.84-1.4%N/A-13.8%$277.19M$246.72M-25.471,130RNACCartesian Therapeutics2.4627 of 5 stars$10.19-4.2%$40.00+292.5%-39.8%$276.66M$38.91M-0.1964Positive NewsCADLCandel Therapeutics2.3616 of 5 stars$5.10+2.0%$20.00+292.2%-27.1%$274.48M$120K-7.3960MNPRMonopar Therapeutics3.3345 of 5 stars$41.48-6.2%$69.57+67.7%+1,146.1%$272.77MN/A-12.4610Analyst ForecastNMRANeumora Therapeutics2.9135 of 5 stars$1.66-1.2%$7.14+330.3%-86.3%$272.07MN/A-1.06108News CoveragePositive NewsLXEOLexeo Therapeutics2.7844 of 5 stars$5.25+4.6%$15.33+192.1%-47.5%$271.09M$650K-1.6158Positive News Related Companies and Tools Related Companies TVRD Alternatives NGNE Alternatives LFCR Alternatives MREO Alternatives ACB Alternatives RNAC Alternatives CADL Alternatives MNPR Alternatives NMRA Alternatives LXEO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
